HRP980532B1 - Novel crystalline torasemide modification - Google Patents

Novel crystalline torasemide modification

Info

Publication number: HRP980532B1
Authority: HR; Croatia
Prior art keywords: torasemide; new; preparation; modification; form iii
Prior art date: 1998-10-02

Application number

HR980532A

Other languages

English (en)

Inventor

Fili Darko

Dumi� Miljenko

Danilovski Aleksandar

Klepi� Bo�ena

Fistri� Ines

Ore�i� Marina

Horvat-Mikul�i� Jasna

Original Assignee

Pliva

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-02

Filing date

1998-10-02

Publication date

2005-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10946825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP980532(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-10-02 Application filed by Pliva filed Critical Pliva

1998-10-02 Priority to HR980532A priority Critical patent/HRP980532B1/xx

1999-10-01 Priority to SI9930744T priority patent/SI1117643T1/xx

1999-10-01 Priority to RU2001111831/04A priority patent/RU2210569C2/ru

1999-10-01 Priority to SK423-2001A priority patent/SK4232001A3/sk

1999-10-01 Priority to NZ510898A priority patent/NZ510898A/xx

1999-10-01 Priority to PT99949272T priority patent/PT1117643E/pt

1999-10-01 Priority to CN99811710A priority patent/CN1125049C/zh

1999-10-01 Priority to ES99949272T priority patent/ES2237158T3/es

1999-10-01 Priority to AT99949272T priority patent/ATE286024T1/de

1999-10-01 Priority to IDW20010958A priority patent/ID29931A/id

1999-10-01 Priority to EP99949272A priority patent/EP1117643B1/de

1999-10-01 Priority to TR2001/00909T priority patent/TR200100909T2/xx

1999-10-01 Priority to IL14215099A priority patent/IL142150A0/xx

1999-10-01 Priority to ZA200102451A priority patent/ZA200102451B/en

1999-10-01 Priority to DE29924789U priority patent/DE29924789U1/de

1999-10-01 Priority to AU62240/99A priority patent/AU759291B2/en

1999-10-01 Priority to BR9915018-2A priority patent/BR9915018A/pt

1999-10-01 Priority to DE69922977T priority patent/DE69922977C5/de

1999-10-01 Priority to PCT/HR1999/000023 priority patent/WO2000020395A1/en

1999-10-01 Priority to UA2001031966A priority patent/UA72895C2/uk

1999-10-01 Priority to JP2000574512A priority patent/JP2002526532A/ja

1999-10-01 Priority to EEP200100194A priority patent/EE04341B1/xx

1999-10-01 Priority to HK02102011.9A priority patent/HK1040250B/zh

1999-10-01 Priority to HU0104009A priority patent/HUP0104009A3/hu

1999-10-01 Priority to DK99949272T priority patent/DK1117643T3/da

1999-10-01 Priority to CZ20011031A priority patent/CZ20011031A3/cs

1999-10-01 Priority to PL99346975A priority patent/PL346975A1/xx

1999-10-01 Priority to CA002345789A priority patent/CA2345789A1/en

1999-10-01 Priority to KR10-2001-7004079A priority patent/KR100437307B1/ko

1999-10-01 Priority to YU24001A priority patent/YU24001A/sh

1999-11-05 Priority to US09/434,439 priority patent/US6399637B1/en

2000-12-31 Publication of HRP980532A2 publication Critical patent/HRP980532A2/hr

2001-03-30 Priority to NO20011633A priority patent/NO317107B1/no

2001-05-02 Priority to BG105485A priority patent/BG105485A/xx

2002-03-13 Priority to US10/096,277 priority patent/US6833379B2/en

2004-06-21 Priority to US10/871,667 priority patent/US20040229919A1/en

2005-06-30 Publication of HRP980532B1 publication Critical patent/HRP980532B1/xx

2006-02-21 Priority to US11/357,109 priority patent/US20060205951A1/en

2007-07-03 Priority to US11/822,274 priority patent/US20070276015A1/en

Links

NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title abstract 5
229960005461 torasemide Drugs 0.000 title abstract 5
230000004048 modification Effects 0.000 title abstract 3
238000012986 modification Methods 0.000 title abstract 3
239000013078 crystal Substances 0.000 abstract 2
230000020477 pH reduction Effects 0.000 abstract 2
208000001953 Hypotension Diseases 0.000 abstract 1
230000003266 anti-allergic effect Effects 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000001773 anti-convulsant effect Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
239000001961 anticonvulsive agent Substances 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
239000002934 diuretic Substances 0.000 abstract 1
230000001882 diuretic effect Effects 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000021822 hypotensive Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
150000007522 mineralic acids Chemical class 0.000 abstract 1
150000007524 organic acids Chemical class 0.000 abstract 1
235000005985 organic acids Nutrition 0.000 abstract 1
238000000634 powder X-ray diffraction Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Liquid Crystal Substances (AREA)
Enzymes And Modification Thereof (AREA)
Pyridine Compounds (AREA)
Medicinal Preparation (AREA)
Liquid Crystal (AREA)

HR980532A 1998-02-10 1998-10-02 Novel crystalline torasemide modification HRP980532B1 (en)

Priority Applications (37)

Application Number	Priority Date	Filing Date	Title
HR980532A HRP980532B1 (en)	1998-10-02	1998-10-02	Novel crystalline torasemide modification
YU24001A YU24001A (sh)	1998-10-02	1999-10-01	Nova kristalna modifikacija torasemida
PCT/HR1999/000023 WO2000020395A1 (en)	1998-10-02	1999-10-01	New crystal modification iii of torasemide
UA2001031966A UA72895C2 (uk)	1998-10-02	1999-10-01	Нова кристалічна модифікація n торасеміду
SK423-2001A SK4232001A3 (en)	1998-10-02	1999-10-01	New crystal modification iii of torasemide
NZ510898A NZ510898A (en)	1998-10-02	1999-10-01	Crystal modification N of torasemide
PT99949272T PT1117643E (pt)	1998-10-02	1999-10-01	Nova modificacao n cristalina de torasemida
CN99811710A CN1125049C (zh)	1998-10-02	1999-10-01	托拉沙得新晶体变型n
ES99949272T ES2237158T3 (es)	1998-10-02	1999-10-01	Nueva modificcion cristalina n de torasemida.
AT99949272T ATE286024T1 (de)	1998-10-02	1999-10-01	Neue kristallmodifikation n von torasemid
IDW20010958A ID29931A (id)	1998-10-02	1999-10-01	Modifikasi kristal torasemida
EEP200100194A EE04341B1 (et)	1998-10-02	1999-10-01	Torasemiidi kristallmodifikatsioon N, selle valmistamismeetod, kasutamine ja ravimvorm
TR2001/00909T TR200100909T2 (tr)	1998-10-02	1999-10-01	Torasemid'in yeni kristal modifikasyonu.
IL14215099A IL142150A0 (en)	1998-10-02	1999-10-01	New crystal modification iii of torasemide
ZA200102451A ZA200102451B (en)	1998-10-02	1999-10-01	New crystal modification III of torasemide.
DE29924789U DE29924789U1 (de)	1998-10-02	1999-10-01	Neue Kristallmodifikation N von Torasemid
AU62240/99A AU759291B2 (en)	1998-10-02	1999-10-01	New crystal modification N of torasemide
BR9915018-2A BR9915018A (pt)	1998-10-02	1999-10-01	Modificação de cristal da torasemida
DE69922977T DE69922977C5 (de)	1998-10-02	1999-10-01	Neue Kristallmodifikation von Torasemid
SI9930744T SI1117643T1 (en)	1998-10-02	1999-10-01	New crystal modification n of torasemide
JP2000574512A JP2002526532A (ja)	1998-10-02	1999-10-01	トラセミドの新規な結晶変態ｎ型
RU2001111831/04A RU2210569C2 (ru)	1998-10-02	1999-10-01	Кристаллическая модификация n-тораземида, способ ее получения, фармацевтическая форма
EP99949272A EP1117643B1 (de)	1998-10-02	1999-10-01	Neue kristallmodifikation n von torasemid
HK02102011.9A HK1040250B (zh)	1998-10-02	1999-10-01	托拉沙得新晶體變型n
HU0104009A HUP0104009A3 (en)	1998-10-02	1999-10-01	New crystal modification of torasemide, process for its preparation, its use as a ran material and pharmaceutical compositions containing it
DK99949272T DK1117643T3 (da)	1998-10-02	1999-10-01	Ny krystalmodifikation N af torasemid
CZ20011031A CZ20011031A3 (cs)	1998-10-02	1999-10-01	Nová krystalová modifikace torasemidu
PL99346975A PL346975A1 (en)	1998-10-02	1999-10-01	New crystal modification iii of torasemide
CA002345789A CA2345789A1 (en)	1998-10-02	1999-10-01	New crystal modification iii of torasemide
KR10-2001-7004079A KR100437307B1 (ko)	1998-10-02	1999-10-01	토라세미드의 새로운 결정 변형태 ⅲ
US09/434,439 US6399637B1 (en)	1998-02-10	1999-11-05	Crystal modification of torasemide
NO20011633A NO317107B1 (no)	1998-10-02	2001-03-30	Ny krystallmodifikasjon av torasemid, fremgangsmate for fremstilling derav, samt farmasoytisk preparat
BG105485A BG105485A (en)	1998-10-02	2001-05-02	New crystal modification n of torasemide
US10/096,277 US6833379B2 (en)	1998-10-02	2002-03-13	Crystal modification of torasemide
US10/871,667 US20040229919A1 (en)	1998-10-02	2004-06-21	Crystal modification of torasemide
US11/357,109 US20060205951A1 (en)	1998-10-02	2006-02-21	New crystal modification of torasemide
US11/822,274 US20070276015A1 (en)	1998-10-02	2007-07-03	Crystal modification of torasemide

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HR980532A HRP980532B1 (en)	1998-10-02	1998-10-02	Novel crystalline torasemide modification

Publications (2)

Publication Number	Publication Date
HRP980532A2 HRP980532A2 (en)	2000-12-31
HRP980532B1 true HRP980532B1 (en)	2005-06-30

Family

ID=10946825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR980532A HRP980532B1 (en)	1998-02-10	1998-10-02	Novel crystalline torasemide modification

Country Status (32)

Country	Link
US (5)	US6399637B1 (de)
EP (1)	EP1117643B1 (de)
JP (1)	JP2002526532A (de)
KR (1)	KR100437307B1 (de)
CN (1)	CN1125049C (de)
AT (1)	ATE286024T1 (de)
AU (1)	AU759291B2 (de)
BG (1)	BG105485A (de)
BR (1)	BR9915018A (de)
CA (1)	CA2345789A1 (de)
CZ (1)	CZ20011031A3 (de)
DE (2)	DE29924789U1 (de)
DK (1)	DK1117643T3 (de)
EE (1)	EE04341B1 (de)
ES (1)	ES2237158T3 (de)
HK (1)	HK1040250B (de)
HR (1)	HRP980532B1 (de)
HU (1)	HUP0104009A3 (de)
ID (1)	ID29931A (de)
IL (1)	IL142150A0 (de)
NO (1)	NO317107B1 (de)
NZ (1)	NZ510898A (de)
PL (1)	PL346975A1 (de)
PT (1)	PT1117643E (de)
RU (1)	RU2210569C2 (de)
SI (1)	SI1117643T1 (de)
SK (1)	SK4232001A3 (de)
TR (1)	TR200100909T2 (de)
UA (1)	UA72895C2 (de)
WO (1)	WO2000020395A1 (de)
YU (1)	YU24001A (de)
ZA (1)	ZA200102451B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6394707B1 (en)	1997-05-08	2002-05-28	Jack Kennedy Metal Products & Buildings, Inc.	Yieldable mine roof support
HRP980532B1 (en)	1998-10-02	2005-06-30	Pliva	Novel crystalline torasemide modification
JP2003527319A (ja) *	1999-08-11	2003-09-16	テバファーマシューティカルインダストリーズリミティド	トルセミド多形体
DE10013289A1 (de) *	2000-03-17	2001-09-20	Knoll Ag	Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en)	2000-03-20	2004-06-30	Pliva D D	Amorphous torasemide modification
HRP20000328A2 (en) *	2000-05-19	2002-02-28	Pliva Farmaceutska Ind Dionik	Novel polymorph v of torasemide
IN192178B (de)	2001-08-03	2004-03-06	Ranbaxy Lab
HRP20020603B1 (en) *	2002-07-19	2008-11-30	Pliva D.D.	New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
CA2424644A1 (en) *	2003-04-07	2004-10-07	David John Mckenzie	Preparation of torasemide
US20050065183A1 (en) *	2003-07-31	2005-03-24	Indranil Nandi	Fexofenadine composition and process for preparing
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
JP4406845B2 (ja) *	2007-02-20	2010-02-03	トヨタ自動車株式会社	二次電池電極材の剥離剤及び該剥離剤を用いた二次電池の処理方法
EP2705843A1 (de) *	2012-09-05	2014-03-12	Pharnext	Therapeutische Ansätze zur Behandlung von Epilepsie und zugehöriger Erkrankungen durch Reduzierung der Epileptogenese
CN104370805B (zh) *	2013-08-13	2016-09-07	天津汉瑞药业有限公司	托拉塞米化合物
CN106038500A (zh) *	2016-05-26	2016-10-26	南京正科医药股份有限公司	一种托拉塞米片
CN115417810B (zh) *	2022-09-22	2023-10-10	南京正科医药股份有限公司	一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) *	2023-12-29	2024-02-02	江西中医药大学	一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4055650A (en) *	1974-04-17	1977-10-25	A. Christiaens Societe Anonyme	Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
GB1477664A (en) *	1974-04-17	1977-06-22	Christiaens Sa A	Pyridine derivatives
US4473693A (en)	1978-08-04	1984-09-25	Stewart Walter W	Aminonaphthalimide dyes for intracellular labelling
DE3529529A1 (de) *	1985-08-17	1987-02-19	Boehringer Mannheim Gmbh	Verfahren zur herstellung einer stabilen modifikation von torasemid
US6166041A (en) *	1995-10-11	2000-12-26	Euro-Celtique, S.A.	2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
HRP980532B1 (en)	1998-10-02	2005-06-30	Pliva	Novel crystalline torasemide modification
US5914336A (en) *	1998-06-02	1999-06-22	Boehringer Mannheim Gmbh	Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) *	1998-06-02	2000-12-26	Roche Diagnostics Gmbh	Torasemide of modification III

1998
- 1998-10-02 HR HR980532A patent/HRP980532B1/xx not_active IP Right Cessation
1999
- 1999-10-01 BR BR9915018-2A patent/BR9915018A/pt not_active IP Right Cessation
- 1999-10-01 RU RU2001111831/04A patent/RU2210569C2/ru not_active IP Right Cessation
- 1999-10-01 EP EP99949272A patent/EP1117643B1/de not_active Revoked
- 1999-10-01 ID IDW20010958A patent/ID29931A/id unknown
- 1999-10-01 HU HU0104009A patent/HUP0104009A3/hu unknown
- 1999-10-01 YU YU24001A patent/YU24001A/sh unknown
- 1999-10-01 IL IL14215099A patent/IL142150A0/xx unknown
- 1999-10-01 JP JP2000574512A patent/JP2002526532A/ja active Pending
- 1999-10-01 KR KR10-2001-7004079A patent/KR100437307B1/ko not_active Expired - Fee Related
- 1999-10-01 HK HK02102011.9A patent/HK1040250B/zh not_active IP Right Cessation
- 1999-10-01 EE EEP200100194A patent/EE04341B1/xx not_active IP Right Cessation
- 1999-10-01 CZ CZ20011031A patent/CZ20011031A3/cs unknown
- 1999-10-01 SI SI9930744T patent/SI1117643T1/xx unknown
- 1999-10-01 PT PT99949272T patent/PT1117643E/pt unknown
- 1999-10-01 TR TR2001/00909T patent/TR200100909T2/xx unknown
- 1999-10-01 DE DE29924789U patent/DE29924789U1/de not_active Expired - Lifetime
- 1999-10-01 AT AT99949272T patent/ATE286024T1/de not_active IP Right Cessation
- 1999-10-01 AU AU62240/99A patent/AU759291B2/en not_active Ceased
- 1999-10-01 CA CA002345789A patent/CA2345789A1/en not_active Abandoned
- 1999-10-01 DK DK99949272T patent/DK1117643T3/da active
- 1999-10-01 ES ES99949272T patent/ES2237158T3/es not_active Expired - Lifetime
- 1999-10-01 CN CN99811710A patent/CN1125049C/zh not_active Expired - Fee Related
- 1999-10-01 NZ NZ510898A patent/NZ510898A/xx unknown
- 1999-10-01 DE DE69922977T patent/DE69922977C5/de not_active Revoked
- 1999-10-01 SK SK423-2001A patent/SK4232001A3/sk not_active Application Discontinuation
- 1999-10-01 WO PCT/HR1999/000023 patent/WO2000020395A1/en not_active Ceased
- 1999-10-01 ZA ZA200102451A patent/ZA200102451B/en unknown
- 1999-10-01 PL PL99346975A patent/PL346975A1/xx not_active Application Discontinuation
- 1999-10-01 UA UA2001031966A patent/UA72895C2/uk unknown
- 1999-11-05 US US09/434,439 patent/US6399637B1/en not_active Expired - Fee Related
2001
- 2001-03-30 NO NO20011633A patent/NO317107B1/no unknown
- 2001-05-02 BG BG105485A patent/BG105485A/xx unknown
2002
- 2002-03-13 US US10/096,277 patent/US6833379B2/en not_active Expired - Fee Related
2004
- 2004-06-21 US US10/871,667 patent/US20040229919A1/en not_active Abandoned
2006
- 2006-02-21 US US11/357,109 patent/US20060205951A1/en not_active Abandoned
2007
- 2007-07-03 US US11/822,274 patent/US20070276015A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1040250A1 (en)	2002-05-31
AU6224099A (en)	2000-04-26
DE69922977C5 (de)	2008-12-24
CZ20011031A3 (cs)	2001-08-15
DE69922977T2 (de)	2005-12-08
US6399637B1 (en)	2002-06-04
NZ510898A (en)	2002-10-25
PL346975A1 (en)	2002-03-11
WO2000020395A1 (en)	2000-04-13
PT1117643E (pt)	2005-05-31
CN1321149A (zh)	2001-11-07
KR100437307B1 (ko)	2004-06-25
DE69922977D1 (de)	2005-02-03
NO20011633L (no)	2001-03-30
ZA200102451B (en)	2001-09-28
US20070276015A1 (en)	2007-11-29
CA2345789A1 (en)	2000-04-13
HUP0104009A3 (en)	2002-04-29
AU759291B2 (en)	2003-04-10
EE200100194A (et)	2002-06-17
BR9915018A (pt)	2001-08-14
UA72895C2 (uk)	2005-05-16
US20060205951A1 (en)	2006-09-14
EP1117643B1 (de)	2004-12-29
US20030055258A2 (en)	2003-03-20
DK1117643T3 (da)	2005-03-29
BG105485A (en)	2002-01-31
NO317107B1 (no)	2004-08-09
IL142150A0 (en)	2002-03-10
ES2237158T3 (es)	2005-07-16
HUP0104009A2 (hu)	2002-02-28
US20020147346A1 (en)	2002-10-10
RU2210569C2 (ru)	2003-08-20
TR200100909T2 (tr)	2001-07-23
EE04341B1 (et)	2004-08-16
KR20010079962A (ko)	2001-08-22
HK1040250B (zh)	2004-03-05
JP2002526532A (ja)	2002-08-20
YU24001A (sh)	2003-02-28
US6833379B2 (en)	2004-12-21
ID29931A (id)	2001-10-25
US20040229919A1 (en)	2004-11-18
SK4232001A3 (en)	2001-10-08
HRP980532A2 (en)	2000-12-31
DE29924789U1 (de)	2005-08-25
CN1125049C (zh)	2003-10-22
EP1117643A1 (de)	2001-07-25
ATE286024T1 (de)	2005-01-15
SI1117643T1 (en)	2005-06-30
NO20011633D0 (no)	2001-03-30

Legal Events

Date	Code	Title	Description
2000-12-31	A1OB	Publication of a patent application
2001-06-20	AIPI	Request for the grant of a patent on the basis of a substantive examination of a patent application
2005-06-30	B1PR	Patent granted
2008-09-08	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20080908 Year of fee payment: 11
2010-04-03	PBON	Lapse due to non-payment of renewal fee	Effective date: 20091003

Publication	Publication Date	Title
HRP980532B1 (en)	2005-06-30	Novel crystalline torasemide modification
CA2360557A1 (en)	2001-05-25	Biodegradable and thermosensitive polyphosphazenes and their preparation method
HRPK20000092B1 (hr)	2001-10-31	Polimorfne modifikacije 2-(3-cijano-4-izobutiloksifenil)-4-metil-5-tiazol-karboksilne kiseline i postupak njihova dobivanja
DE69504663D1 (de)	1998-10-15	KATHODENMATERIAL FÜR Li-SEKUNDÄRBATTERIEN UND VERFAHREN UND VORLÄUFERMATERIAL ZU DEREN HERSTELLUNG
CA2248953A1 (en)	1998-07-16	Novel benzofuranone derivatives and process for producing the same
WO1997013774A3 (fr)	1997-05-29	Nouveaux derives de la 5-o-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
CA2091616A1 (en)	1993-09-18	Method for manufacturing powdery crystalline maltitol
AU2866989A (en)	1989-10-05	Diurea derivatives useful as medicaments and processes for the preparation thereof
MY110352A (en)	1998-04-30	Process for preparing 4-demethoxydaunorubicin.
WO1999007691A3 (de)	1999-04-08	Verfahren zur herstellung von l-ascorbinsäure
JPH10106566A5 (de)	2004-09-24
EP1195356A4 (de)	2006-06-07	Plattenförmiges metalltitanat-komposit und verfahren zu dessen herstellung
AU3300893A (en)	1993-09-23	Diacetyl production
CA2297112A1 (en)	1999-03-04	Dicyclanil polymorphs and hydrates and their preparation
JPS6471844A (en)	1989-03-16	2,4,5-trifluoroisophthalonitrile and production thereof
CA2234344A1 (en)	1997-04-17	New crystalline form of morphine-6-glucuronide
IE800864L (en)	1980-10-30	Pyrimidine derivatives
CA2252952A1 (en)	1997-11-06	Substituted aminomethylphenylsulphonylureas, their preparation, and their use as herbicides and plant growth regulators
Zachwieja	1993	Single Crystal Growth and Structure Refinement of NaAu sub 2--a New Synthesis Method for Alkali Metal--Gold Compounds
AU5390094A (en)	1994-03-17	Chiral lactic acid derivatives
JPS5435197A (en)	1979-03-15	Preparation of zinc hydroxide platy crystals
Maurer et al.	1994	Process for producing hydroxylapatite
AU7652794A (en)	1995-03-21	Novel phenyl glyoxylic acid derivatives, processes for producing them and their use as herbicides and plant growth regulators
EP0400558A3 (de)	1992-03-04	Phenylessigsäurederivat
Xue et al.	1995	Crystal structure of EuAu sub 2 Al sub 2